Recent

% | $
Quotes you view appear here for quick access.

Affymax, Inc. Message Board

  • ezgi.ulusoy ezgi.ulusoy Sep 18, 2013 9:47 PM Flag

    Read again feb/13/2013

    As we complete the analysis in the next week or two we plan to provide an update on the pilot experience and any future recommendations. I thank you for your participation in determining best protocols and practices around the use of OMONTYS® and we will update you with the analysis of our experience once complete.

    With best regards,

    Franklin W. Maddux, MD, FACP
    Chief Medical Officer
    Executive VP For Clinical and Scientific Affairs
    Fresenius Medical Care North America

    Jeffrey L. Hymes, MD
    Associate Chief Medical Officer
    Fresenius Medical Care North America



    We are now working to analyze the full set of efficacy and safety profile information and feel that the current scale of our experience with use of the drug is adequate to complete this analysis. These results will be presented to our Corporate Medical Advisory Board with follow up reporting to our medical staff. In the meantime, this communication is to inform you of our confirmation of the adjusted prescribing information and the finding that such allergic reactions can occur in patients receiving the first dose of the drug. For patients on OMONTYS®, we recommend continued use of the agent as it has been providing effective anemia management. We plan to pause the rollout to additional facilities and patients at this time until the analyses are complete and reported to our medical staff. As many of you have become quite comfortable with the medication, physicians and facilities that have been using OMONTYS® who wish to continue prescribing it for new patients may choose to do so.



    As we complete the analysis in the next week or two we plan to provide an update on the pilot experience and any future recommendations. I thank you for your participation in determining best protocols and practices around the use of OMONTYS® and we will update you with the analysis of our experience once complete.



    With best regards,



    Franklin W. Maddux, MD, FACP
    Chief Medical Officer
    Executive VP For Clinical and Scientific Affairs

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • When was the Fresenius roll out ever a "pilot program"? Orwin specifically denied Fresenius was an O pilot program at the time it was begun. Instead, Orwin described it as a Fresenius "conversion program" to Omontys use. Only after the trouble arose did it become recharacterized as a "pilot" program to be "paused." That was just one clue of many if you were "able to read between the lines" of the Fresenius letter and go short AFFY at the time of the letter's publication as did I.

      • 1 Reply to godwinpeak
      • Here's more lines to read between.
        Thu July 12, 2012 8:00 AM
        "The agreement, which ends in April 2013, allows Fresenius Medical CareNorth America to purchase OMONTYS for use in U.S. centers within its organization and provides for discounts and rebates on the product, subject to certain requirements. Fresenius Medical Care North Americahas stated that its initial plans are to adopt the product into more than 100 dialysis centers in the U.S. over the next few weeks, and then, based on its experience, evaluate the potential to expand to additional centers. Financial terms were not disclosed."

    • Were you able to "read between the lines" in the same fashion as GeedoubleUPee? Did you find it? The part about the deaths. I tried and I tried but I must confess my eyesight isn't what it use to be.

    • Doesn't make any sense! What are you trying to say? That's before the recall.. Sell before you can...

      • 1 Reply to stn10427
      • "That's before the recall" exactly, now show us where the reported deaths are that GeedoubleUPee referred to. I suspect someone with loose lips tipped off shorts to the recall coming next week. A point the shareholders lawsuit probably overlooked. I'm hoping someone in a regulatory position is looking into the possibility of insider trading connected to the 11 million shares traded Feb 14.

 
AFFY
0.075-0.0010(-1.32%)Jun 28 3:37 PMEDT